Avantor (AVTR) Set to Announce Earnings on Thursday

Avantor (NYSE:AVTR – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, April 28th. Analysts expect the company to announce earnings of $0.35 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Avantor (NYSE:AVTR – Get Rating) last released its earnings results on Thursday, February 3rd. The company reported $0.36 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.03. The company had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.90 billion. Avantor had a return on equity of 35.81% and a net margin of 7.53%. During the same period in the prior year, the business posted $0.29 EPS. On average, analysts expect Avantor to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

AVTR stock opened at $32.73 on Thursday. The stock has a market capitalization of $19.96 billion, a price-to-earnings ratio of 38.06, a PEG ratio of 0.68 and a beta of 1.62. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.11 and a current ratio of 1.71. Avantor has a 1 year low of $29.58 and a 1 year high of $44.37. The stock’s fifty day moving average is $33.65 and its two-hundred day moving average is $36.99.

AVTR has been the subject of a number of research reports. Robert W. Baird decreased their price objective on Avantor from $44.00 to $43.00 in a research report on Monday, February 7th. Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and cut their price target for the stock from $48.00 to $38.00 in a report on Monday, April 4th. Raymond James cut their target price on Avantor from $43.00 to $40.00 and set an “outperform” rating for the company in a research note on Monday. Barclays upped their price target on Avantor from $41.00 to $44.00 and gave the company an “overweight” rating in a research report on Monday, February 7th. Finally, Zacks Investment Research cut Avantor from a “hold” rating to a “sell” rating in a report on Monday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Avantor has an average rating of “Buy” and an average price target of $43.59.

In other news, EVP Gerard Brophy sold 3,059 shares of the business’s stock in a transaction dated Wednesday, February 23rd. The stock was sold at an average price of $33.79, for a total value of $103,363.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in AVTR. KB Financial Partners LLC purchased a new stake in shares of Avantor in the 4th quarter worth $68,000. Belpointe Asset Management LLC bought a new position in shares of Avantor in the 4th quarter valued at about $224,000. Toroso Investments LLC lifted its holdings in shares of Avantor by 37.5% in the 4th quarter. Toroso Investments LLC now owns 12,602 shares of the company’s stock valued at $531,000 after acquiring an additional 3,439 shares during the last quarter. JustInvest LLC lifted its holdings in shares of Avantor by 12.8% in the 4th quarter. JustInvest LLC now owns 12,605 shares of the company’s stock valued at $531,000 after acquiring an additional 1,433 shares during the last quarter. Finally, Guggenheim Capital LLC lifted its stake in Avantor by 74.8% in the fourth quarter. Guggenheim Capital LLC now owns 18,880 shares of the company’s stock worth $795,000 after purchasing an additional 8,076 shares during the last quarter. 92.46% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile (Get Rating)

Avantor, Inc provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Featured Articles